LXRXLEXICON PHARMACEUTICALS, INC.同业对比
LEXICON PHARMACEUTICALS, INC. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LXRX本股 | $627M#4 | — | 3.6x#7 | 12.6x#3 | 60.2%#2 | 74.9%#3 | -98.2%#3 | -28.8%#3 | -26.4%#3 | — | 1.8%#2 | — |
| AVBP | $675M#1 | — | 1.8x#2 | — | — | -106.6%#11 | — | -45.3%#7 | — | — | — | — |
| APMD | $659M#2 | — | — | — | — | — | — | — | — | — | — | — |
| DSGN | $651M#3 | — | 3.2x#6 | — | — | -40.7%#9 | — | -34.6%#4 | — | — | 59.9%#1 | — |
| OLMA | $598M#5 | — | 1.4x#1 | — | — | -25.5%#7 | — | -37.7%#5 | — | — | — | — |
| NVCT | $596M#6 | — | 65.6x#9 | — | — | -39.2%#8 | — | -291.1%#10 | — | — | — | — |
| ZVRA | $593M#7 | 10.7x#2 | 2.7x#5 | 5.6x#2 | 350.9%#1 | 178.9%#2 | -59.1%#2 | 38.2%#1 | — | — | -1.8%#3 | — |
| ANNX | — | — | — | — | — | -49.6%#10 | — | -111.1%#9 | — | — | — | — |
| IRWD | $581M#8 | 4.4x#1 | — | 2.0x#1 | -15.7%#3 | 2629.5%#1 | 33.3%#1 | — | 42.6%#1 | — | — | — |
| GERN | $578M#9 | — | 2.6x#4 | 2440.0x#5 | -60.2%#5 | 52.2%#4 | -28938.8%#5 | -38.2%#6 | -24.8%#2 | — | — | — |
| ACRS | $567M#10 | — | 4.5x#8 | 72.4x#4 | -58.2%#4 | 50.8%#5 | -975.9%#4 | -52.1%#8 | -65.8%#4 | 3#1 | — | — |
| CLYM | $565M#11 | — | 2.4x#3 | — | — | 19.0%#6 | — | -25.0%#2 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-03。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议